Cargando…
Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer
PURPOSE: This study investigated the clinical impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) on survival in patients with oligometastatic breast cancer. PATIENTS AND METHODS: We collected data from 397 patients who underwent primary breast surgery from 2004 to 2015 and developed recurre...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581831/ https://www.ncbi.nlm.nih.gov/pubmed/36153381 http://dx.doi.org/10.1007/s10549-022-06726-w |
_version_ | 1784812715946016768 |
---|---|
author | Inoue, Yuka Fujishima, Makoto Ono, Makiko Masuda, Jun Ozaki, Yukinori Maeda, Tetsuyo Uehiro, Natsue Takahashi, Yoko Kobayashi, Takayuki Sakai, Takehiko Osako, Tomo Ueno, Takayuki Ohno, Shinji |
author_facet | Inoue, Yuka Fujishima, Makoto Ono, Makiko Masuda, Jun Ozaki, Yukinori Maeda, Tetsuyo Uehiro, Natsue Takahashi, Yoko Kobayashi, Takayuki Sakai, Takehiko Osako, Tomo Ueno, Takayuki Ohno, Shinji |
author_sort | Inoue, Yuka |
collection | PubMed |
description | PURPOSE: This study investigated the clinical impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) on survival in patients with oligometastatic breast cancer. PATIENTS AND METHODS: We collected data from 397 patients who underwent primary breast surgery from 2004 to 2015 and developed recurrence during the follow-up. We reviewed the images and clinical information and defined OMD according to the European Society for Medical Oncology advanced breast cancer guidelines. The NLR was calculated using pretreatment data of primary breast cancer. The cutoff value of the NLR was determined by receiver operating characteristic curve with Youden Index. RESULTS: Among 397 patients, 131 had OMD at recurrence. The low-NLR group included patients of significantly older age at primary cancer than those in the high-NLR group. A low NLR indicated a better overall survival (p = 0.023) after adjusting for relevant factors, including estrogen receptor status, surgical resection of metastatic disease, metastatic organ number, disease-free interval, and liver metastasis than did the high-NLR group. We developed prognostic models for OMD using six independent prognostic factors, including the NLR. The number of factors was associated with overall survival; patients with all six favorable factors showed a good overall survival of 90.9% at 8 years and those with four or more factors showed 70.4%. CONCLUSIONS: The NLR was an independent prognostic factor for overall survival in OMD. The number of favorable prognostic factors was associated with overall survival. A prognostic model, including the NLR, will help identify patients with a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06726-w. |
format | Online Article Text |
id | pubmed-9581831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-95818312022-10-21 Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer Inoue, Yuka Fujishima, Makoto Ono, Makiko Masuda, Jun Ozaki, Yukinori Maeda, Tetsuyo Uehiro, Natsue Takahashi, Yoko Kobayashi, Takayuki Sakai, Takehiko Osako, Tomo Ueno, Takayuki Ohno, Shinji Breast Cancer Res Treat Clinical Trial PURPOSE: This study investigated the clinical impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) on survival in patients with oligometastatic breast cancer. PATIENTS AND METHODS: We collected data from 397 patients who underwent primary breast surgery from 2004 to 2015 and developed recurrence during the follow-up. We reviewed the images and clinical information and defined OMD according to the European Society for Medical Oncology advanced breast cancer guidelines. The NLR was calculated using pretreatment data of primary breast cancer. The cutoff value of the NLR was determined by receiver operating characteristic curve with Youden Index. RESULTS: Among 397 patients, 131 had OMD at recurrence. The low-NLR group included patients of significantly older age at primary cancer than those in the high-NLR group. A low NLR indicated a better overall survival (p = 0.023) after adjusting for relevant factors, including estrogen receptor status, surgical resection of metastatic disease, metastatic organ number, disease-free interval, and liver metastasis than did the high-NLR group. We developed prognostic models for OMD using six independent prognostic factors, including the NLR. The number of factors was associated with overall survival; patients with all six favorable factors showed a good overall survival of 90.9% at 8 years and those with four or more factors showed 70.4%. CONCLUSIONS: The NLR was an independent prognostic factor for overall survival in OMD. The number of favorable prognostic factors was associated with overall survival. A prognostic model, including the NLR, will help identify patients with a favorable prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06726-w. Springer US 2022-09-24 2022 /pmc/articles/PMC9581831/ /pubmed/36153381 http://dx.doi.org/10.1007/s10549-022-06726-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Trial Inoue, Yuka Fujishima, Makoto Ono, Makiko Masuda, Jun Ozaki, Yukinori Maeda, Tetsuyo Uehiro, Natsue Takahashi, Yoko Kobayashi, Takayuki Sakai, Takehiko Osako, Tomo Ueno, Takayuki Ohno, Shinji Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer |
title | Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer |
title_full | Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer |
title_fullStr | Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer |
title_full_unstemmed | Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer |
title_short | Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer |
title_sort | clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581831/ https://www.ncbi.nlm.nih.gov/pubmed/36153381 http://dx.doi.org/10.1007/s10549-022-06726-w |
work_keys_str_mv | AT inoueyuka clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT fujishimamakoto clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT onomakiko clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT masudajun clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT ozakiyukinori clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT maedatetsuyo clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT uehironatsue clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT takahashiyoko clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT kobayashitakayuki clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT sakaitakehiko clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT osakotomo clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT uenotakayuki clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer AT ohnoshinji clinicalsignificanceoftheneutrophiltolymphocyteratioinoligometastaticbreastcancer |